Two methods for the measurement of plasma creatine kinase MB (CK-MB) activity were compared for analytical performance, cost, practicality, and diagnostic correlation with clinical and electrocardiographic findings in patients admitted to the coronary care unit of a district general hospital. The methods were column chromatography and immunoinhibition. Both methods were found acceptable, and the method to be adopted would depend on the staff arrangements and resources available in the laboratory. 197 
Creatine kinase MB (CK-MB), an iso-enzyme of CK (EC 2.7.3.2) (Burger et al., 1964) , is consistently released into the circulation after myocardial infarction showing a specific and rapid response (Roe et al., 1972) . After an infarct it first appears in the plasma within four hours (Roberts et al., 1977) and reaches a peak at between J6 and 24 hours (Wagner et al., 1973) ; the levels fal1 to normal after 48 hours (Roe et al., 1972) . Plasma activity remains low after cardioversion (Konttinen and Somer, 1973) , coronary angiography (Wagner et al., 1973) , pulmonary embolus (Somer and Konttinen, 1972) , angina pectoris (Wolf and Kearns, 1974) , arrythmias or pericarditis (Fiolet et al., 1977) , intramuscular injection (Rao et al., 1975; Roberts et al., 1975; Ahumada et al., 1976) , or exercise (Kaman et al., 1977) . CK-MB activity is detectable in normal plasma, but only at low activity, and the conditions other than myocardial infarction (MI), in which it is significantly increased, such as Duchenne muscular dystrophy (Konttinen and Somer, 1973) , crush injury (Wilhelm and Todd, 1977) , and acromegalic myopathy (Wolf and Griffith, 1978) , are not usually considered in the differential diagnosis of Ml.
Use of CK-MB could help a diagnosis to be reached not only for those patients with old electrocardiographic (ECG) changes such as bundle-branch block, where enzymes have always been of value, but also in those infarct patients in whom the ECG is not diagnostic in the early hours (Wagner et al., 1973; Rosalki, 1977) . In addition, it has been shown that the level of increased CK-MB activity correlates directly with infarct size, decrease of cardiac function, and postmortem findings (Sobel et al., 1972; Shel1 and Sobel, 1976) . The rapid response is also of value in the diagnosis of re-infarction (Neumeier et al., 1976) when taken along with other findings; a second peak of increased CK-MB activity can be interpreted as diagnostic of further cardiac infarction (Roe et al., [972) .
Several analytical methods have been described for the determination of CK-MB. Agarose gel electrophoresis is reliable and sensitive (Griffiths and Handschuh, 1977) but is relatively slow and difficult to quantify in the routine laboratory (Jockers-Wretou and Pfleiderer, 1975; Butte et al., 1977; Fiolet et al., J977) . Selective activation has poor discrimination and is not specific (Balkcom, 1976; Morin, 1977; Willis et al., 1978) . Radioimmunoassay compares well with other methods but is timeconsuming, and at present it is not suitable for the routine laboratory . We compared an ion-exchange chromatography method with an immunoinhibition method to determine which was the most suitable for use in a district general hospital (Wong and Smith, 1975) .
Patients and methods
Consecutive patients admitted to the coronary care unit (CCU) at St Mary's Hospital, Eastbourne were investigated. Blood samples were taken at regular intervals, and CK-MB assay was performed on each sample by the two methods; 10 ml blood was taken at 4-hourly intervals over the first 48 hours after admission (with the exception of 0400) using an indwelling catheter in an arm vein. To overcome loss of enzyme activity after collection, activating agents were added to the samples. For the ion-exchange chromatography method,S ml of each sample was placed in a sequestrene (ethylenediamine tetra-acetic acid) tube (Sandifort, 1977; Bruns et 01., 1978; Gruber, 1978; Rollo et al., 1978; Waldenstrom et 01., 1978) , and for the immunoinhibition method 5 ml was placed in a lithium heparin tube, to which had been added 2 III mercaptoethanol (MEC) and 9·5 mg of ethyleneglycol-bis-(aminoethyl-ether)-tetra-acetic acid to give a final concentration of 5 mmol/I, It was shown in this laboratory that when whole blood was treated and stored in this way the activity of CK-MB in the specimen was maintained for one week (Swan, 1979) .
The samples were stored at 4 c,C for 12-72 hours (depending on the day and time of collection, but usually for less than 24 hours). They were then centrifuged, and separated, and the plasma was stored at -15°C until analysis within 72 hours. The ionexchange column chromatography system used was the Boehringer Mannheim kit (marketed by BCL, Bell Lane, Lewes, East Sussex, Product No. 189219) which is based on the Mercer (1974) method using a Sephadex A-50 column for separation of the CK iso-enzymes. The eluate containing the CK-MB fraction was assayed for CK activity using BCL Kit No. 126357, which uses the dithiol N-acetyl-cysteine (NAC) as activator. The Merck kit (marketed by BDH Chemicals Ltd, Poole, Dorset, Product No. 143(0) was used for the immunoinhibition method (Neumeier et 01., 1976; Wurzburg et al., 1977) with glutathione as activator. Since October 1978 this kit has used NAC as activator, and thus collection into sequestrene is now used for both methods.
The procedure for the column chromatography method was as set out in the kit instructions, but for the immunoinhibition method the Merck kit was modified by using 650 III of reconstituted reagent instead of the recommended 2000 III (to obtain 90 tests instead of 30 from each kit) and scaling down the other volumes commensurately. The time for antibody inhibition was also reduced from 7 to 3 minutes, because this was a mode available on the reaction rate analyser used, and because inhibition is known to be complete after 3 minutes (Neumeier et 01., 1976) .
For both methods the CK activity (Rosalki, 1967 ) of the specimen after treatment was measured using a Gilford 3401N reaction rate analyser at 25°C. The reference values for inpatients, including those with cardiac conditions but excluding any patients with infarction, were 0-8 V/I (with mean values of 3·4 V/I (immunoinhibition) and 2·9 V/I (column chromatography) determined kinetically using a Pye-Unicarn SP1700 spectrophotometer in parallel with the reaction rate analyser assay). Nealon and Henderson (1975) , using a modified Mercer method, found up to 6'8 V/I of CK-MB activity in normal sera.
Of a total of 169 patients studied, 104 were considered to have suffered an MI, including two patients readmitted with a second infarct. A diagnosis of MI was confirmed on the basis of a typical history, ECG changes compatible with the WHO classification (1968), and an increase of at least twice the reference value for the plasma enzymes aspartate amino transferase (AST; EC 2.6.1.1) and n-hydroxybutyrate dehydrogenase (HBD).
Forty-six patients were diagnosed as having noninfarct pain and a further 12 patients, who were considered clinically to have suffered infarcts, were excluded because their ECG changes failed to satisfy WHO criteria for infarction; these patients are discussed later. Five patients were excluded from the analysis because it was impossible to time the onset of their symptoms and two patients because not enough blood samples were obtainable. The clinical analysis, therefore, concerns 102 patients with infarcts (a total of 104 infarcts) and 46 patients with chest pain but no infarct.
Findings
A total of 3852 plasma CK-MB determinations were performed. There were 1904 assays using the column chromatography kit and 1948 assays using the immunoinhibition kit. The range of values obtained and the 2-hourly means for CK-MB levels on patients who had suffered a myocardial infarction and those without an infarct are shown respectively in Tables 1 and 2 and Figure 1 .
Easily interpretable peaks were obtained for 95 patients by the column chromatography method and for 92 patients by the immunoinhibition method ( Fig. 2) with mean time from onset of symptoms to peak values of 22'5 (SD 8'7) hours and 25·6 (SD 9,7) hours respectively. The difference in the timing of the peaks was not significant (Student's t test). In some patients, although CK-MB acnvity reached twice normal, the levels oscillated, rendering it impossible to determine the precise time interval from the onset of symptoms to the peak of the enzyme activity (Fig. 3) . Partly because of this scatter of the peak values and partly because some patients were not in hospital until many hours after the onset of their symptoms (in this series 14 were not admitted within 16 hours), no single time of sampling gave a definite diagnosis in every patient, and it was therefore necessary to consider two or more samples. If two samples were taken, 16 and 32 hours after the onset of symptoms were the times that gave the best diagnostic yield: 93 out of 104 diagnoses confirmed by the column chromatography method, 90 out of 104 by the immunoinhibition method (see Figs. 4 and 5 and Table 3 ). Sampling three times, at 16, 24, and 32 hours, increased the yield to 92 with the immunoinhibition method but did not increase that of the column chromatography method.
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With specimens taken at 0800 for two days after admission (which could be a routine procedure in a CCU), 84 % of infarct patients had significantly raised CK-MB by column chromatography and 85 % by the immunoinhibition method. By each method four patients who had fulfilled the conventional criteria for the diagnosis of MI failed to achieve twice normal levels of CK-MB at any time and would, therefore, not have been diagnosed by CK-MB assay alone. These are discussed further below. In general, the over 90% agreement of serial CK-MB assay and clinical findings represents a highly satisfactory diagnostic yield. (Daily plasma AST assay is performed as a routine on CCU r 15:
. , l/ In all patients not suffering infarcts, CK-MB levels, determined by the column chromatography method, were consistently within the normal range, but the immunoinhibition method yielded twice normal levels in two patients and three times normal levels in one patient (Fig. 6) . Electrophoresis was performed on the same samples used for this immunoinhibition CK-MB assay, but CK-BB isoenzyme was not detected. This maximum of a 6 % false-positive rate compares with a rate of 10 % for total CK and 15 /~for AST found in these CCU non-infarct patients. The within-batch and betweenbatch coefficients of variation were determined using two levels of CK-MB activity (the results are 
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METHODOLOGY
The Merck (immunoinhibition) kit was simple to use, although not supplied in an automated kit form. No separating stage was necessary, and only 25 ul of serum was required. The BCL (column chromatography) kit used a greater volume of sample (500 1-11) and had the disadvantage that the assay took longer to complete. At least half an hour was required to separate the isoenzymes of each specimen, but the working time of this stage was reduced by batching samples so that 20 separations could be performed in 30 minutes.
The cost per test of the two kits was comparable in 1978. The BCL column chromatography method required two kits, one for the separation of the CK iso-enzyme (20 tests at £5·90 per kit) and the other for the estimation of the CK activity in the eluate. The CK-NAC kit (at £27'50) was sufficient, in our hands, to perform 180 estimations. The total cost for the BCL techniq ue was thus 44p per test. The Merck kit, which cost £43,56, contained 30 x 2·0 ml test vials which, in our hands, were used for 90 tests at a cost of 48p each. The Merck kit had no hidden costs in that reagents were made up using supplied buffer. The BCL kit reagents had to be reconstituted with water. (For comparison, the cost of our AST tests is about 2p each.)
The reagents in the Merck kit were supplied in test vials and, once reconstituted, were stable for only 24 hours at 4°C. The BCL reagents were stable for six months.
The BCL kit results were not affected by haemolysis at levels of less than 200 rngjdl (2g/l) haemoglobin. The Merck kit used in this survey required plasma free of haemolysis.
The BCL kit contained two vials of quality control sera which were treated in a similar fashion to the specimens. During the time of this survey a quality control for the Merck method was not obtainable. Controls were put through with the specimens for CK assay but the completeness and specificity of the antibody reaction remained uncontrolled. It has been reported that inhibition of the MB dimer activity by CK-M inhibiting antibodies can vary between 45 % and 56 % (Wurzburg et al., 1977) , and the inhibiting antibodies for the reagent mixture, raised against human M subunits, will not inhibit the M fraction in control sera of animal origin, and even 'human control sera' have CK-MB activities derived from animal sources. The range of M inhibition probably represents differences either in the specified activity against creatine phosphate of the M and B subunits or possibly an allosteric effect .A .6. column chromatography method;
shown in Table 4 ). To determine the within-batch variation for the column chromatography method, 20 test samples were obtained by assaying 20 pooled aliquots of CK-MB control. For the immunoinhibition method, an identical number of pooled patient samples were used. Precision was more acceptable for the column chromatography method. This was due partly to the factor that had to be incorporated into the determination of the absorbance change for the irnrnunoinhibition method to compensate for the inhibited M subunits so that, under the best conditions, with the rate reaction analyser used it was not possible to discriminate CK-MB activity of less than 8 VII.
on the CK-B subunit in the dimer by the antibodybound M subunit. This lack of specificity (together with the multiplication factor, which has to be applied to all results by the Merck method) contributed to the poorer precision found for this method.
If the choice of methodology is to be decided by factors such as accuracy and precision, the column chromatography method should be used; if the choice is governed by considerations of time and labour then the irnmunoinhibition method should be used; but both methods are suitable for the routine clinical chemistry laboratory.
We did consider whether CK-MB activity should be expressed as a percentage of total CK because, although heart muscle is richest in CK-MB, the iso-enzyme does occur in small amounts in other muscle. In skeletal muscle damage, the CK-MB activity could be increased, but it would remain a small percentage of the increased total CK. Varat and Mercer (1975) showed that in conditions other than MI the CK-MB level remained less than 4 % of total CK. During this survey every patient also had total CK assayed on each specimen, and there were occasions when the percentage was of value. For example, in 9 of 11 cases of acute pancreatitis (all with serum amylase activity of over 1000 IU/l) the CK-MB activity was less than 16 U/l; the other two cases, however, had a percentage CK-MB of less than 6%. All the patients with increased CK-MB activity due to MI had a CK-MB percentage of over 6 % (by both methods) and, using a manual spectrophotometer (Pye-Unicam SPI700), all non-MI patients had a CK-MB of less than 6~õ f the total CK. With reaction rate analysers (Gilford or Vitatron Akes), which for routine work were less sensitive over the lower ranges, falsely raised percentages could be obtained on non-MI cases, when a CK-MB of 0-8 U/I (but reported as 8 U jl) could derive a percentage of over 6 %.
CLINICAL VALUE
In keeping with general clinical practice, a level of twice normal or higher of all the enzymes measured was accepted as indicative of tissue damage. For CK-MB, a level of 16 U/I or more was taken as diagnostic of MI. This agreed with the clinical findings for the column chromatography method, but the immunoinhibition method yielded a 6 % false-positive rate in the non-infarct patients.
Possible explanations for these false-positive results include: contamination with CK-BB (Mercer, 1977; Jung et al., 1979) ; variation in the antibody inhibition of CK-M activity; and any inaccuracy inherent in the method would be doubled by the multiplication factor used in calculating the results.
Although the above clinical analysis includes only infarct patients who satisfied the WHO criteria for the diagnosis of MI, we found the measurement of CK-MB useful for certain patients excluded from the survey because the significance of their ECG changes was difficult to interpret. In these patients, taking into account the clinical and CK-MB findings, a confident diagnosis of Ml was made in five patients admitted with left bundle-branch block, in three patients where infarction appeared to have occurred on the site of a previous infarct, and in four patients where changes in the ECG were minimal.
Since the purpose of this survey was to follow CK-MB levels while the patient was in the CCU, it was not designed to determine the value of serial CK-MB assays in the diagnosis of reinfarction. During the survey, samples were occasionally taken on patients after transfer to other wards, and in one patient reinfarction was diagnosed on the reappearance of CK-MB activity on the fourth day and confirmed clinically.
The timing of the symptom/sample collection interval depended upon the ability of patients to be able to state the time their symptoms started. Some patients found this difficult, especially when the initial symptoms were of a vague or intermittent nature. In these cases, infarction was judged to start from when the symptoms became severe. On reexamining the case histories, it appeared that incorrect timing of the onset of the infarct (as suggested by the patient's history) accounted for the normal levels of CK-MB found in four patients in whom the clinical and ECG findings satisfied the WHO criteria for the diagnosis of MI.
We conclude that creatine kinase MB is the enzyme of choice for the diagnosis of MI if the patient is seen within 36 hours of the onset of symptoms. The method of choice for a laboratory performing up to 50 cardiac enzyme tests a day, and able to put aside part of a laboratory worker's time just for this assay, is the column chromatography method, but if the numbers to be assayed are greater the laboratory will probably find the irnmunoinhibition method more practical and just as acceptable. From the clinical aspect, collection is into a standard sequestrene container, and for a clear diagnostic peak of enzyme activity the best times for collection are 16 and 32 hours after MI.
We thank Roussel Laboratories Ltd for financial help in support of this project.
